GNNSF (Genscript Biotech) Additional Paid-In Capital : $1,981.5 Mil(As of Dec. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Genscript Biotech Additional Paid-In Capital?

Genscript Biotech's quarterly additional paid-in capital increased from Dec. 2023 ($1,939.3 Mil) to Jun. 2024 ($1,974.7 Mil) and increased from Jun. 2024 ($1,974.7 Mil) to Dec. 2024 ($1,981.5 Mil).

Genscript Biotech's annual additional paid-in capital increased from Dec. 2022 ($1,473.0 Mil) to Dec. 2023 ($1,939.3 Mil) and increased from Dec. 2023 ($1,939.3 Mil) to Dec. 2024 ($1,981.5 Mil).

Genscript Biotech Additional Paid-In Capital Historical Data

The historical data trend for Genscript Biotech's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genscript Biotech Additional Paid-In Capital Chart

Genscript Biotech Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Additional Paid-In Capital

Get a 7-Day Free Trial

1,274.27

1,473.03

1,939.26

1,981.53

Genscript Biotech Semi-Annual Data
	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Additional Paid-In Capital	Get a 7-Day Free Trial															1,473.03	1,923.70	1,939.26	1,974.66	1,981.53

Genscript Biotech Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Genscript Biotech Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Genscript Biotech's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Genscript Biotech Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genscript Biotech Corp (OTCPK:GNNSF) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

01548:Hong Kong G51:Germany

Address

No. 28, Yongxi Road, Jiangning Science Park, Jiangsu Province, Nanjing, CHN, 211100

Website

https://www.genscript.com

Genscript Biotech Corp is a China-based provider of life science research services and products. The firm is known for its gene synthesis capabilities, a widely used service by academics, biotech companies, and pharmaceutical companies around the world. The company's business segments include Life-science services and products, Biologics development services, Industrial synthetic biology products, and the Operation unit. The company generates the majority of its revenue from the life-science services and products unit, which provides comprehensive research services and products, which are widely used and are fundamental to life-science research and application. Geographically, the company generates the majority of its revenue from the United States of America, followed by Mainland China.